From Google Scholar & other sources: Selected Journal Articles, Newsletters, Dissertations, Theses, Commentary
Cryptococcosis remains a significant cause of morbidity and mortality world-wide, particularly among AIDS patients. Yet, to date, there are no licensed vaccines clinically available to treat or prevent cryptococcosis. In this review, we provide a rationale to support continued investment in Cryptococcus vaccine research, potential challenges that must be overcome along the way, and a literature review of the current progress underway towards developing a vaccine to prevent cryptococcosis
:: Expansion of Cryptococcus in unique patient populations and environmental niches highlights the need for a prophylactic vaccine to prevent cryptococcosis caused by virulent C. neoformans and C. gattii.
:: Vaccination with heat-killed Cryptococcus mutants containing cell-wall modifications appears to induce protective immune responses against cryptococcosis in mice.
:: Experimental studies show potential for eliciting long-lasting protective immunity against cryptococcosis in CD4+ T cell-deficient hosts.
:: Administration of fungal glycolipids, such as glucosylceramide, demonstrates significant protection against subsequent Cryptococcus infection in mice.
:: Mice vaccinated with an innovative β-glucan antigen-delivery platform containing immune stimulatory Cryptococcus fractions have protective anticryptococcal immune responses against virulent strains of C. neoformans and C. gattii.